OncoSil Medical (ASX:OSL) received Medical Device Regulation certification from the European Union notified body BSI Group, according to a Tuesday filing with the Australian bourse.
The certification includes the lifting of existing post-market restrictions for the OncoSil cancer treatment device, simplifying the initiation of commercial treatments, the filing said.
The certification also offers the company a chance to re-submit its application to the Therapeutic Goods Administration for Australian market approval, according to the filing.
Oncosil shares surged 20% in recent trade Wednesday.
Price (AUD): $0.01, Change: $+0.0010, Percent Change: +20.00%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.